查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010053

鎮痛藥市場：2026-2032年全球市場預測（依藥物類型、給藥途徑、適應症及通路分類）

Analgesics Market by Type of Drug, Route of Administration, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年止痛藥市值為449.6億美元，預計2026年將成長至479.9億美元，複合年成長率為7.04%，到2032年將達到724.3億美元。

主要市場統計數據
基準年 2025 449.6億美元
預計年份：2026年 479.9億美元
預測年份 2032 724.3億美元
複合年成長率 (%) 7.04%

對不斷發展的鎮痛生態系統進行簡要概述，重點關注影響臨床需求、監管壓力和相關人員策略的創新促進因素。

目前鎮痛藥的發展現況正處於臨床需求、監管和治療方法快速進步的交會點。患者和臨床醫生都渴望獲得有效、安全且易於獲得的急性和慢性疼痛管理方案，而製藥公司則面臨著鴉片類藥物管控、製劑創新和供應鏈韌性方面的嚴峻挑戰。在此背景下，公共的討論和新型給藥技術的出現正在重塑鎮痛藥的研發、分銷和應用方式。

展望未來，概述臨床、技術和監管方面的變化，這些變化正在重新定義研發路徑、處方行為和分銷策略。

鎮痛領域正經歷著一場變革性的轉變，這場變革是由臨床、技術和政策因素共同推動的。在臨床上，對多方面疼痛管理的日益重視提升了非鴉片類藥物療法和輔助治療策略的重要性，從而減少了對高劑量鴉片類藥物處方的依賴，同時為開發針對特定疼痛類型的差異化製劑創造了機會。藥物科學領域的技術進步，例如緩釋基質和經皮給藥平台，正在拓展治療選擇，並實現更精準的給藥方案。

透過證據分析，探討美國在 2025 年前的關稅措施將如何重塑整個止痛藥價值鏈的供應鏈、籌資策略和業務永續營運。

貿易政策決策的累積影響，包括美國計畫在2025年前實施的關稅措施，正為止痛藥供應鏈和製造業經濟帶來新的複雜性。影響原料、活性藥物成分和成品的關稅措施可能會增加依賴全球供應商網路的製造商和契約製造製造商的採購成本。為此，各公司正在重新審視其籌資策略，尋求將某些投入品近岸外包，並協商簽訂長期供應商契約，以穩定投入成本並最大限度地減少生產中斷。

從詳細的細分觀點，將藥物類別、給藥途徑、臨床適應症和通路聯繫起來，以指導產品設計和管道策略。

市場區隔洞察揭示了臨床需求與商業性機會的交匯點，對產品、給藥途徑、適應症和分銷動態的詳細分析有助於明確創新和投資重點。根據藥物類型，市場分為非鴉片類藥物和鴉片類藥物。非鴉片類藥物包括對乙醯胺酚、非類固醇消炎劑和水楊酸鹽，而鴉片類藥物則進一步細分為可待因、Fentanyl、氫可酮、氫可酮和羥考酮，每種藥物都有其獨特的臨床應用特徵和監管考慮。根據給藥途徑，可選擇肌肉注射、靜脈注射、口服、直腸給藥、局部用藥和經皮給藥，其中口服劑型又分為膠囊和錠劑。每種給藥途徑都面臨不同的製劑挑戰和病患依從性問題。

對美洲、歐洲、中東和非洲以及亞太地區的監管多樣性、支付方優先事項和分銷複雜性進行區域評估，這些因素會影響准入和分銷。

區域趨勢影響需求模式、監管預期和分銷重點，對美洲、歐洲、中東和非洲以及亞太地區的影響各不相同。在美洲，醫療保健系統和支付方結構優先考慮急性護理和門診慢性疼痛管理的效率，尤其重視鴉片類藥物的管理，這影響著處方行為和藥物在處方藥清單中的納入。美洲的監管和報銷環境通常鼓勵開展以真實臨床實踐中的療效和安全性為重點的證據研究，這影響著臨床應用和採購決策。

競爭分析強調，基於證據的差異化、策略夥伴關係和供應鏈敏捷性是鎮痛領域長期成功的決定因素。

鎮痛藥市場的競爭格局由成熟的製藥公司、專業生產商和專注於製劑和給藥技術的創新新興企業組成。市場領導者往往憑藉臨床證據、安全性以及供應鏈可靠性展開競爭，而新參與企業則透過創新的給藥平台、濫用預防功能和針對性適應症策略脫穎而出。生物製藥公司與技術提供者之間的合作日益普遍，從而能夠整合數位健康元素，以支持藥物依從性和真實世界數據（REW）的收集。

為高階主管提供可操作的建議，以協調產品創新、供應鏈韌性、證據生成和夥伴關係與不斷變化的臨床和監管重點。

產業領導企業應優先採取策略措施，使產品開發與臨床實務、監管要求以及具有韌性的供應鏈設計相契合，以保持競爭優勢。首先，投資於防濫用功能和以病人為中心的配方，既能滿足臨床需求，又能符合監管要求。專注於開發既能降低濫用風險又能維持鎮痛效果的給藥系統，將贏得處方醫生和保險公司的支持。其次，透過供應商多元化、關鍵原料近岸採購以及提高庫存透明度來增強供應鏈韌性，可以降低貿易政策波動和意外中斷帶來的風險。

透明且有系統的研究途徑，結合專家訪談、文獻整合和迭代檢驗，為可靠的見解奠定了基礎，這些見解可以立即用於決策。

本研究採用多面向方法，結合一手質性訪談、二手文獻整合和結構化資料檢驗，以確保獲得可靠且可操作的見解。一手研究包括對臨床醫生、處方集管理人員、監管事務專家和供應鏈高階主管進行專家訪談，以了解相關人員對臨床效用、處方趨勢、監管限制和營運風險的觀點。這些訪談優先考慮直接參與鎮痛藥選擇、採購和患者管理的從業人員和決策者，從而確保研究結果基於真實的臨床實踐。

一份簡潔的總結，整合了臨床趨勢、監管考慮、供應鏈挑戰和細分市場優先事項，以指南策略規劃。

總而言之，鎮痛藥產業目前正經歷重大變革，其驅動力包括臨床變革時期轉向多元化疼痛管理、監管機構對安全性和預防濫用問題的重視，以及證明藥物實際價值的商業性壓力。這些趨勢既為生產商和經銷商帶來了挑戰，也帶來了機會。挑戰包括應對貿易政策和監管複雜性對供應鏈的影響，而機會則體現在差異化製劑、替代給藥系統以及能夠改善治療效果和提高用藥依從性的整合數位化支持等領域。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按藥物類型分類的鎮痛藥市場

  • 非鴉片類藥物
    • 乙醯胺酚
    • 非類固醇消炎劑
    • 水楊酸
  • 鴉片類藥物
    • 可待因
    • Fentanyl
    • 氫可酮
    • 氫可酮
    • 羥考酮

第9章：止痛藥市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈注射（IV）
  • 口服
    • 膠囊
    • 藥片
  • 直腸
  • 外用
  • 經皮

第10章：鎮痛藥市場：依適應症分類

  • 急性疼痛
    • 與創傷相關的疼痛
    • 術後疼痛
  • 慢性疼痛
    • 關節炎
    • 腰痛
    • 癌症疼痛
    • 神經性疼痛

第11章 鎮​​痛藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：止痛藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 止痛藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 鎮痛藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國止痛藥市場

第16章：中國止痛藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • CSPC Pharmaceutical Group
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Haleon plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck KGaA
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05184

The Analgesics Market was valued at USD 44.96 billion in 2025 and is projected to grow to USD 47.99 billion in 2026, with a CAGR of 7.04%, reaching USD 72.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.96 billion
Estimated Year [2026] USD 47.99 billion
Forecast Year [2032] USD 72.43 billion
CAGR (%) 7.04%

A concise introduction to the evolving analgesics ecosystem highlighting clinical demand, regulatory pressures, and innovation drivers shaping stakeholder strategies

The analgesics landscape sits at the intersection of clinical need, regulatory scrutiny, and rapid therapeutic innovation. Patients and clinicians demand effective, safe, and accessible pain management options across acute and chronic conditions, while manufacturers face pressing challenges related to opioid stewardship, formulation innovation, and supply chain resilience. Against this backdrop, public policy debates and emerging delivery technologies are reshaping how analgesics are developed, distributed, and adopted.

Recent years have seen a shift from one-size-fits-all prescribing towards more nuanced, patient-centric approaches that weigh efficacy, safety, and abuse potential. This dynamic is motivating new product development in both non-opioid and opioid categories, as well as renewed interest in alternative routes of administration that can improve adherence and reduce systemic exposure. Simultaneously, payers and health systems are scrutinizing real-world outcomes and cost-effectiveness more closely, which is influencing formulary decisions and adoption timelines.

As a result, stakeholders across the value chain-manufacturers, clinicians, distributors, and regulators-must balance short-term operational imperatives with longer-term strategic planning. This introductory perspective frames the subsequent sections, offering a lens through which to interpret technological, regulatory, and commercial developments that will influence product life cycles and patient outcomes in the near to medium term.

A forward-looking synthesis of clinical, technological, and regulatory shifts that are redefining development pathways, prescribing behavior, and distribution strategies

The analgesics landscape is undergoing transformative shifts driven by converging clinical, technological, and policy forces. Clinically, the emphasis on multimodal pain management has elevated non-opioid therapies and adjunctive strategies, reducing reliance on high-dose opioid prescribing while creating opportunities for differentiated formulations that target specific pain types. Technological advances in formulation science, including controlled-release matrices and transdermal platforms, are expanding therapeutic options and enabling more precise dosing regimens.

On the regulatory front, heightened vigilance around opioid-related harms continues to influence labeling, prescribing guidelines, and post-market surveillance requirements. This has prompted manufacturers to innovate not only at the molecular level but also in risk-mitigation strategies, such as abuse-deterrent formulations and integrated patient education programs. Meanwhile, digital health tools are beginning to integrate with analgesic care pathways, offering remote monitoring, adherence support, and real-world data capture that can inform clinical decision-making and payer negotiations.

Commercially, distribution and access models are evolving as healthcare purchasers prioritize value-based outcomes. Retail, hospital, and online pharmacy channels are each adapting to new consumer expectations and regulatory requirements. These shifts are creating a more complex competitive landscape where agility in regulatory compliance, supply chain management, and evidence generation confers a strategic advantage. Taken together, these transformative dynamics are redefining how analgesic therapies are developed, evaluated, and delivered to patients.

An evidence-based analysis of how United States tariff measures through 2025 could reshape supply chains, sourcing strategies, and operational resilience across the analgesics value chain

The cumulative effects of trade policy decisions, including tariff actions instituted by the United States through 2025, are adding a new layer of complexity to analgesics supply chains and manufacturing economics. Tariff measures affecting raw materials, active pharmaceutical ingredients, and finished goods can increase procurement costs for manufacturers and contract manufacturers that rely on global supplier networks. In response, firms are reevaluating sourcing strategies, nearshoring certain inputs, and negotiating longer-term supplier agreements to stabilize input costs and minimize production disruptions.

These adjustments carry operational implications that extend beyond procurement. Manufacturers may need to revisit production scheduling, inventory buffers, and contractual terms with distributors to absorb or pass through incremental cost pressures while maintaining compliance with pricing transparency and reimbursement rules. Additionally, increased input costs can influence decisions regarding formulation selection and packaging, prompting a reassessment of cost-to-serve across different routes of administration and product formats.

Beyond direct cost impacts, tariff-driven supply chain shifts have strategic ramifications for market access and competitiveness. Companies with diversified manufacturing footprints and vertically integrated supply chains are better positioned to manage tariff-related volatility, while smaller players and those with concentrated sourcing may face heightened operational risk. In light of these challenges, stakeholders should apply scenario planning to identify critical supply nodes, stress-test supplier alternatives, and prioritize investments that enhance supply chain visibility and agility. By anticipating tariff-induced disruptions and implementing pragmatic mitigation measures, organizations can preserve continuity of care and support resilient access to analgesic therapies.

A detailed segmentation-driven perspective connecting drug classes, delivery routes, clinical indications, and distribution pathways to guide product design and channel strategies

Segmentation insights reveal where clinical demand intersects with commercial opportunity, and a granular view of product, delivery, indication, and distribution dynamics helps clarify priorities for innovation and investment. Based on type of drug, the market divides into non-opioids and opioids; non-opioids encompass acetaminophen, non-steroidal anti-inflammatory drugs, and salicylates, while opioids are further segmented into codeine, fentanyl, hydrocodone, morphine, and oxycodone, each with distinct clinical use profiles and regulatory considerations. Based on route of administration, the landscape includes intramuscular, intravenous, oral, rectal, topical, and transdermal delivery options, with oral formats further differentiated into capsules and tablets, and each route implicating different formulation challenges and patient adherence patterns.

Based on indication, pain management needs are categorized into acute and chronic pain; acute pain includes injury-related and postoperative pain where rapid onset and predictable duration are priorities, while chronic pain covers conditions such as arthritis, back pain, cancer pain, and neuropathic pain where long-term safety, tolerability, and functional outcomes matter most. Based on distribution channel, access is governed by hospital pharmacies, online pharmacies, and retail pharmacies, each channel imposing different requirements around inventory management, patient counseling, regulatory compliance, and reimbursement procedures.

Taken together, these segmentation dimensions highlight areas for targeted development. For example, formulations tailored to chronic neuropathic pain may prioritize sustained-release oral or transdermal delivery and require robust tolerability data, while postoperative care solutions emphasize rapid-onset IV or intramuscular products alongside clear protocols for tapering. Channel strategies must align with patient touchpoints: hospital pharmacies are critical for inpatient and perioperative management, retail pharmacies for community access and chronic therapy continuity, and online pharmacies for convenience and adherence support. Integrating these segment-level insights supports product design choices, evidence strategies, and go-to-market planning that reflect real-world clinical use and distribution realities.

A regionalized appraisal of regulatory diversity, payer priorities, and distribution complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access and adoption

Regional dynamics influence demand patterns, regulatory expectations, and distribution priorities, with distinct implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems and payer structures emphasize both acute care efficiency and outpatient chronic pain management, with strong attention to opioid stewardship that shapes prescribing behavior and formulary placement. Regulatory and reimbursement environments in the Americas often incentivize evidence generation focused on real-world effectiveness and safety, which affects clinical adoption and procurement decisions.

In Europe, Middle East & Africa, regulatory frameworks vary considerably across jurisdictions, driving the need for localized regulatory strategies and region-specific clinical evidence. Access pathways and distribution models are heterogeneous, ranging from highly centralized national health systems to fragmented private markets, which requires tailored approaches to pricing, reimbursement dossiers, and supply chain logistics. The Asia-Pacific region presents a diverse set of market conditions where rapid urbanization, expanding healthcare infrastructure, and growing demand for patient-centric therapies are accelerating uptake of novel formulations and alternative delivery systems. However, regulatory harmonization is uneven across the region, necessitating strategic sequencing of country launches and adaptive regulatory engagement.

Across all regions, differences in healthcare financing, physician prescribing norms, and patient expectations mean that global product strategies must be adaptable. Manufacturers should align clinical development plans, pharmacovigilance activities, and distribution partnerships with regional priorities to optimize adoption and ensure consistent supply while respecting local regulatory and cultural contexts. This regionalized approach supports more effective resource allocation and mitigates the risk of one-size-fits-all strategies in a geographically diverse global market.

A competitive analysis emphasizing evidence-driven differentiation, strategic partnerships, and supply chain agility as determinants of long-term success in analgesics

Competitive dynamics in analgesics are shaped by a mix of established pharmaceutical companies, specialty manufacturers, and emerging innovators focused on formulation and delivery technologies. Market leaders tend to compete on the basis of clinical evidence, safety profiles, and supply chain reliability, while newer entrants differentiate through novel delivery platforms, abuse-deterrent features, and targeted indication strategies. Partnerships between biopharmaceutical firms and technology providers are becoming more common, enabling the integration of digital health components that support adherence and real-world evidence collection.

Intellectual property strategies remain important where novel molecules or distinctive delivery systems are involved, but competitive positioning increasingly depends on demonstrating real-world benefit and operational excellence across the supply chain. Strategic alliances with contract development and manufacturing organizations, distribution partners, and specialty pharmacies can accelerate market entry and expand reach without necessitating full vertical integration. At the same time, vigilance around pharmacovigilance and regulatory compliance is essential to maintaining trust with prescribers and patients, particularly for opioid therapies.

Going forward, companies that combine robust clinical evidence packages with agile manufacturing footprints and patient-centric service models will be best positioned to capture clinical uptake and sustain long-term relationships with healthcare systems. This requires a coordinated approach that aligns R&D, regulatory, commercial, and supply chain functions to deliver reliable products and measurable outcomes across diverse care settings.

Actionable recommendations for executives to align product innovation, supply chain resilience, evidence generation, and partnerships with evolving clinical and regulatory priorities

Industry leaders should prioritize strategic moves that align product development with clinical practice, regulatory expectations, and resilient supply chain design to maintain competitive advantage. First, investing in abuse-deterrent and patient-centric formulations can address both clinical needs and regulatory scrutiny; focusing development on delivery systems that reduce misuse risk while preserving analgesic efficacy will resonate with prescribers and payers. Second, strengthening supply chain resilience through supplier diversification, nearshoring of critical inputs, and enhanced inventory visibility will mitigate exposure to trade policy shifts and unexpected disruptions.

Third, generating high-quality real-world evidence and health economics data will support reimbursement negotiations and demonstrate value to payers and healthcare systems. Integrating digital tools for adherence monitoring and outcome tracking can augment evidence generation and provide differentiating post-market data. Fourth, tailoring regional launch strategies to local regulatory and payer environments will improve uptake; sequencing launches and adapting promotional messaging to regional clinical norms and distribution channel requirements will optimize resource allocation.

Finally, cultivating strategic partnerships across the ecosystem-from contract manufacturers to specialty pharmacies and digital health vendors-can accelerate commercialization while controlling cost and complexity. By combining these actions, companies can better navigate regulatory pressures, supply chain volatility, and shifting clinical expectations, thereby enhancing the likelihood of sustained adoption and improved patient outcomes.

A transparent and methodical research approach combining expert interviews, literature synthesis, and iterative validation to underpin credible, decision-ready insights

This research employed a multi-method approach combining primary qualitative interviews, secondary literature synthesis, and structured data validation to ensure robust and actionable insights. Primary research involved expert interviews with clinicians, formulary managers, regulatory affairs professionals, and supply chain executives to capture stakeholder perspectives on clinical utility, prescribing trends, regulatory constraints, and operational risks. These conversations prioritized practitioners and decision-makers directly involved in analgesic selection, procurement, and patient management to ground findings in real-world practice.

Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available policy analyses to contextualize trends in analgesic use, safety considerations, and formulation innovations. Where appropriate, regulatory approvals, labeling changes, and guideline updates were reviewed to establish a defensible baseline for analysis. Data triangulation techniques were applied to reconcile differing information sources and to identify consistent patterns that informed segmentation and regional assessments.

Finally, findings were validated through iterative reviews with domain experts and cross-functional stakeholders to confirm interpretability and practical relevance. Limitations were acknowledged explicitly, including the evolving nature of regulatory frameworks and the potential for future policy changes to influence dynamics. This methodological rigor supports the credibility of the conclusions and recommendations presented, while also enabling readers to gauge the applicability of insights to their own strategic contexts.

A concise concluding synthesis that integrates clinical trends, regulatory considerations, supply chain imperatives, and segmentation priorities to guide strategic planning

In summary, the analgesics sector is navigating a period of substantive change driven by clinical shifts toward multimodal pain management, regulatory emphasis on safety and misuse prevention, and commercial pressures that reward evidence of real-world value. These dynamics create both challenges and opportunities for manufacturers and distributors: challenges include managing supply chain exposure to trade policy and regulatory complexity, while opportunities lie in differentiated formulations, alternative delivery systems, and integrated digital support that can improve outcomes and adherence.

Strategically, success will hinge on the ability to align product innovation with payer and prescriber expectations, to build resilient supply chains that absorb policy-induced volatility, and to generate the evidence that convinces healthcare purchasers of clinical and economic value. Regional nuances require tailored approaches to regulatory engagement and market access, and segmentation insights should inform product design choices that match clinical needs with patient preferences and channel realities. By executing on these priorities, organizations can contribute to safer, more effective, and more accessible pain management solutions while protecting commercial performance.

The collective implication is clear: a coordinated, evidence-driven, and regionally sensitive strategy will be essential to navigate near-term disruptions and to position analgesic therapies for long-term relevance in an increasingly outcome-focused healthcare environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Analgesics Market, by Type of Drug

  • 8.1. Non-Opioids
    • 8.1.1. Acetaminophen
    • 8.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.1.3. Salicylates
  • 8.2. Opioids
    • 8.2.1. Codeine
    • 8.2.2. Fentanyl
    • 8.2.3. Hydrocodone
    • 8.2.4. Morphine
    • 8.2.5. Oxycodone

9. Analgesics Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous (IV)
  • 9.3. Oral
    • 9.3.1. Capsules
    • 9.3.2. Tablets
  • 9.4. Rectal
  • 9.5. Topical
  • 9.6. Transdermal

10. Analgesics Market, by Indication

  • 10.1. Acute Pain
    • 10.1.1. Injury-related pain
    • 10.1.2. Postoperative pain
  • 10.2. Chronic Pain
    • 10.2.1. Arthritis
    • 10.2.2. Back pain
    • 10.2.3. Cancer pain
    • 10.2.4. Neuropathic pain

11. Analgesics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Analgesics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Analgesics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Analgesics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Analgesics Market

16. China Analgesics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Bayer AG
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. C.H. Boehringer Sohn AG & Co. KG
  • 17.9. Cipla Limited
  • 17.10. CSPC Pharmaceutical Group
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. GlaxoSmithKline plc
  • 17.14. Grunenthal GmbH
  • 17.15. Haleon plc
  • 17.16. Hikma Pharmaceuticals plc
  • 17.17. Johnson & Johnson Services, Inc.
  • 17.18. Lupin Limited
  • 17.19. Mallinckrodt plc
  • 17.20. Merck KGaA
  • 17.21. Novartis AG
  • 17.22. Perrigo Company plc
  • 17.23. Pfizer Inc.
  • 17.24. Reckitt Benckiser Group plc
  • 17.25. Sanofi S.A.
  • 17.26. Sun Pharmaceutical Industries Limited
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANALGESICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANALGESICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)